Regulus Therapeutics

Regulus Announces $80.9 Million in Total Gross Proceeds from IPO and Other Recent Financial Transactions

November 5, 2012

LA JOLLA, Calif., Nov. 5, 2012 /PRNewswire/ — Regulus Therapeutics Inc. ( NASDAQ : RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, summarized today its recent financing activity that the company expects will enable Regulus to execute its current strategic objectives for the foreseeable future. In connection with Regulus’ Initial […]

Read the full article →

Regulus Announces Pricing of Initial Public Offering

October 4, 2012

LA JOLLA, Calif., Oct. 4, 2012 /PRNewswire/ — Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today the pricing of its initial public offering of 11,250,000 shares of its common stock at $4.00 per share.  Regulus has also granted the underwriters a 30-day option to […]

Read the full article →

MicroRNAs as Biomarkers for Multiple Sclerosis – Biogen Idec and Regulus Therapeutics Form Collaboration

August 15, 2012

Biogen Idec and Regulus Therapeutics Form Collaboration to Explore microRNA Biomarkers for Disease Monitoring and Response to Therapy LA JOLLA, Calif., Aug. 15, 2012 /PRNewswire/ — Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that it has entered into a collaboration with Biogen Idec (NASDAQ: […]

Read the full article →

Regulus Therapeutics Forms Strategic Alliance for Discovery, Development and Commercialization of microRNA Therapeutics with AstraZeneca

August 14, 2012

Focused on three exclusive microRNA targets LA JOLLA, Calif., Aug. 14, 2012 /PRNewswire/ — Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that it has entered into a strategic alliance with AstraZeneca to discover, develop, and commercialize microRNA therapeutics for three exclusive targets which are […]

Read the full article →

Regulus Announces New Publication Showing Potential Therapeutic Benefit of Targeting microRNA-21 in Fibrosis

February 16, 2012

-New study published in Science Translational Medicine demonstrates microRNA-21 contributes to fibrogenesis in the kidney -Regulus, in partnership with Sanofi, developing novel anti-fibrotic therapies targeting microRNAs B.N. Chau et al. “MicroRNA-21 Promotes Fibrosis of the Kidney by Silencing Metabolic Pathways” Sci Transl Med 15 February 2012: Vol. 4, Issue 121, p. 121ra18 Sci. Transl. Med. […]

Read the full article →

Regulus Therapeutics Initiates an Orphan and Rare Disease microRNA Therapeutic Effort in Brain Cancer

December 12, 2011

-Regulus, Accelerate Brain Cancer Cure (ABC2) and Samsung Medical Center to Advance microRNA Therapeutics for Glioblastoma – LA JOLLA, Calif., Dec. 12, 2011 /PRNewswire/ — Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced the initiation of a new discovery effort in microRNA therapeutics for the treatment […]

Read the full article →

Regulus Therapeutics to Present New In Vivo Data for microRNA-21 in Kidney Fibrosis

November 8, 2011

-Regulus Scientists to Provide Update on Lead Therapeutic Program at American Society of Nephrology Meeting- LA JOLLA, Calif., Nov. 8, 2011 /PRNewswire/ — Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced presentations on its preclinical programs for the treatment of fibrosis at the American Association […]

Read the full article →

New Pre-Clinical Data on microRNA-33 Demonstrating Key Role in Cholesterol Homeostasis and Fatty Acid Metabolism

October 20, 2011

New publication in Nature shows therapeutic silencing of microRNA-33a/b for atherosclerosis: Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides K.J. Rayner et al. Nature 478, 404–407 (20 October 2011) http://www.nature.com/nature/journal/v478/n7369/full/nature10486.html Regulus Therapeutics and Collaborators Publish New Pre-Clinical Data on microRNA-33 Demonstrating Key Role in Cholesterol Homeostasis and Fatty Acid Metabolism […]

Read the full article →

Nature Article Implicates microRNAs in the Pathogenesis of Obesity and Type 2 Diabetes

June 9, 2011

– Work of scientists with Regulus, Alnylam and ETH Zurich shows microRNAs 103/107 are upregulated in mouse models of obesity; targeting with anti-miRs improves glucose homeostasis and insulin sensitivity – LA JOLLA, Calif., and CAMBRIDGE, Mass., June 8, 2011 /PRNewswire/ — Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines […]

Read the full article →

Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis

June 6, 2011

Research Article Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis Katey J. Rayner, Frederick J. Sheedy, Christine C. Esau, Farah N. Hussain, Ryan E. Temel, Saj Parathath, Janine M. van Gils, Alistair J. Rayner, Aaron N. Chang, Yajaira Suarez, Carlos Fernandez-Hernando, Edward A. Fisher, Kathryn J. Moore J. Clin. Invest. […]

Read the full article →